title: [Efficacy of TAS-102].
abstract: Of late, there has been rapid development of chemotherapeutic agents for treating metastatic colorectal cancers. However, the so-called "druglag" is a long-standingproblem; it refers to the drugapproval delays in Japan that occur after drugs have been developed and approved in Europe and the USA. Clinical trials for the drugTAS -102 were stopped in the USA, but the drugwas evaluated in phase I and II clinical trials in Japan. The Phase II trial for TAS-102 in Japan provided positive results, and it received approval in Japan first, ahead of the world. Data from the global phase III RECOURSE trial were presented in the ESMO-GI 2014, where the efficacy of TAS-102 was proved again. Herein, we present data about the efficacy and side effects of TAS-102 from each clinical trial.
authors.affiliation: Dept. of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kotani
authors.forename: Shota
authors.initials: S
authors.lastname: Fukuoka
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yoshino
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004338:Drug Combinations; D006801:Humans; D011759:Pyrrolidines; D013941:Thymine; D014271:Trifluridine / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D011759:Pyrrolidines; C000613803:trifluridine tipiracil drug combination; D014498:Uracil; D013941:Thymine; D014271:Trifluridine